Mar 26, 2020 / 08:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus AB-729 Clinical Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Pam Murphy. Thank you, and please go ahead.
Pam Murphy - Arbutus Biopharma Corporation - IR Consultant
Good afternoon, everyone. Hopefully, you've been able to connect to the AB-729 clinical update webinar/webcast and that you are able to access the slides. With me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Mike Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer.
Bill will begin with a quick summary of the data and planned next steps for 729. Gaston will then walk you through Parts 1 and 2 of the 3 part AB-729-001 Phase Ia/Ib clinical trial. We will then open up the call for Q&A after Gaston's presentation.
Before we begin, we
Arbutus Biopharma Corp to Discuss the Preliminary Phase 1a/1b Clinical Trial Results for AB-729 Conference Call Transcript
Mar 27, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers